{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:08:42Z","timestamp":1790723322306,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.numecd.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:33:55Z","timestamp":1605267235000},"page":"869-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience"],"prefix":"10.1016","volume":"31","author":[{"given":"Roberto","family":"Scicali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Urbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Marchisello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-3365","authenticated-orcid":false,"given":"Alessandra","family":"Scamporrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-8823","authenticated-orcid":false,"given":"Agnese","family":"Filippello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata M.","family":"Rabuazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2020.11.009_bib1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.numecd.2020.11.009_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081948","article-title":"Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview","volume":"20","author":"Marchisello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2020.11.009_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.11.009_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2020.11.009_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British society of gastroenterology, the royal college of radiologists and the royal college of pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2020.11.009_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2020.11.009_bib7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2020.11.009_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2012.11.021","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal","volume":"58","author":"Machado","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2020.11.009_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5121574","article-title":"The triglyceride and glucose index is a predictor of incident nonalcoholic fatty liver disease: a population-based cohort study","volume":"2019","author":"Kitae","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2020.11.009_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2020.11.009_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","article-title":"Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases","volume":"126","author":"Cai","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2020.11.009_bib13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.11.009_bib14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib16","article-title":"Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease","author":"Markeli\u0107","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2020.11.009_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-017-1089-4","article-title":"New treatment options for lipid-lowering therapy in subjects with type 2 diabetes","volume":"55","author":"Scicali","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2020.11.009_bib20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","article-title":"Familial hypercholesterolemia treatments: guidelines and new therapies","volume":"277","author":"Raal","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2020.11.009_bib23","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2020.11.009_bib24","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2020.11.009_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2020.11.009_bib27","first-page":"1865","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis","author":"Emma","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.numecd.2020.11.009_bib28","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors","volume":"24","author":"Theocharidou","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.numecd.2020.11.009_bib29","series-title":"PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia","author":"Dimakopoulou","year":"2018"},{"key":"10.1016\/j.numecd.2020.11.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2017.07.003","article-title":"Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile","volume":"28","author":"Scicali","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2018.08.013","article-title":"Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: the LIPIGEN study","volume":"277","author":"Casula","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2020.11.009_bib32","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.11.009_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.30170","article-title":"Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study","volume":"69","author":"Chang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2020.11.009_bib34","doi-asserted-by":"crossref","first-page":"918368","DOI":"10.1155\/2012\/918368","article-title":"Adult current smoking: differences in definitions and prevalence estimates--NHIS and NSDUH, 2008","volume":"2012","author":"Ryan","year":"2012","journal-title":"J Environ Public Health"},{"key":"10.1016\/j.numecd.2020.11.009_bib35","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.11.009_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.11.009_bib37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/cells8080910","article-title":"1 h postload glycemia is associated with low endogenous secretory receptor for advanced glycation end product levels and early markers of cardiovascular disease","volume":"8","author":"Di Pino","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.numecd.2020.11.009_bib38","article-title":"Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a Two\u2013Lipid Center Real-World Experience","volume":"14","author":"Mandraffino","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2020.11.009_bib39","article-title":"Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency","volume":"50","author":"Spadaro","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.numecd.2020.11.009_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56857-2","article-title":"Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation","volume":"9","author":"Scicali","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2020.11.009_bib41","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2337\/dc13-2357","article-title":"Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA 1c according to American diabetes association criteria","volume":"37","author":"Di Pino","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.11.009_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00592-019-01338-1","article-title":"Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia","volume":"56","author":"Scicali","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2020.11.009_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","article-title":"Spectrum of mutations in Italian patients with familial hypercholesterolemia: new results from the LIPIGEN study","volume":"29","author":"Pirillo","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.numecd.2020.11.009_bib44","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.numecd.2014.01.013","article-title":"Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes","volume":"24","author":"Calanna","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12944-017-0409-6","article-title":"The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease","volume":"16","author":"Zhang","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00494.x","article-title":"Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations","volume":"231","author":"Laws","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.numecd.2020.11.009_bib47","article-title":"High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects","author":"Scicali","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2020.11.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2020.05.009","article-title":"Triglyceride to high-density lipoprotein cholesterol ratio and risk of atherosclerotic cardiovascular disease in a Chinese population","author":"Zhou","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.11.009_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009442","article-title":"Triglyceride and triglyceride\/HDL (high density lipoprotein) ratio predict major adverse cardiovascular outcomes in women with non-obstructive coronary artery disease","volume":"8","author":"Prasad","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2020.11.009_bib50","article-title":"Elevated triglycerides to high-density lipoprotein cholesterol (TG\/HDL-C) ratio predicts long-term mortality in high-risk patients","author":"Sultani","year":"2019","journal-title":"Hear Lung Circ"},{"key":"10.1016\/j.numecd.2020.11.009_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/diacare.18.2.193","article-title":"Insulin sensitivity and Lp(a) concentrations in normoglycemic men","volume":"18","author":"Haffner","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.11.009_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vph.2015.04.004","article-title":"Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet\/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and\/or metabolic syndrome","volume":"72","author":"Santilli","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.numecd.2020.11.009_bib53","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/ars.2010.3719","article-title":"What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?","volume":"14","author":"D'Adamo","year":"2011","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.numecd.2020.11.009_bib54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: what is \u201coptimal\u201d?","volume":"14","author":"Aberra","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2020.11.009_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.numecd.2020.11.009_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacl.2019.12.003","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects","volume":"14","author":"Taskinen","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2020.11.009_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9194736","article-title":"The effect of proprotein convertase subtilisin\/kexin type 9 inhibitors on nonfasting remnant cholesterol in a real world population","volume":"2018","author":"Morise","year":"2018","journal-title":"J Lipids"},{"key":"10.1016\/j.numecd.2020.11.009_bib58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J Hepatol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320304853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320304853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:17:16Z","timestamp":1760545036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475320304853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0939475320304853"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2020.11.009","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}